A new pilot study examining LSD microdosing for depression found that adults with major depressive disorder experienced short-term improvements in energy, creativity, happiness, and social connectedness while taking carefully controlled low doses of LSD.
The findings, published in Progress in Neuropsychopharmacology & Biological Psychiatry, arrive at a time when psychiatric researchers are increasingly investigating how psychedelic compounds may influence brain flexibility, emotional processing, and motivation. Unlike traditional antidepressants, which often take weeks to show benefits, psychedelic compounds may produce more rapid shifts in mood and cognition.
Why Researchers Are Studying LSD Microdosing For Depression
Microdosing involves taking very small amounts of a psychedelic substance that are low enough to avoid hallucinations but high enough to potentially affect brain signaling pathways. In recent years, anecdotal reports from individuals using psychedelics outside medical settings have suggested improvements in mood, focus, and emotional resilience.
However, scientific evidence remains limited. Most prior studies focused on healthy volunteers rather than people actively living with depression. The new study attempted to close that gap by evaluating adults formally diagnosed with major depressive disorder.
Researchers enrolled nineteen participants in an eight week open-label trial. Each participant received an initial eight microgram sublingual dose of LSD in a laboratory setting. Afterward, they continued dosing at home twice weekly while using a smartphone application to monitor symptoms and adjust doses within a tightly controlled range.
How The LSD Microdosing Protocol Worked
Participants could increase or decrease their doses depending on how they felt after each session. If the effects interfered with daily functioning, the dose could be lowered. If they noticed little psychological impact, they could gradually increase the amount.
Researchers also collected extensive pharmacokinetic data to understand how the body processed the drug. Blood samples taken during the first laboratory session showed that LSD concentrations peaked slightly more than one hour after administration, closely matching the timing of participants’ reported subjective effects.
The smartphone application tracked several emotional and behavioral measures, including happiness, energy, creativity, irritability, social connectedness, and sleep quality. This continuous monitoring approach gave researchers a detailed view of how mood fluctuated throughout the study period.
LSD Microdosing For Depression Produced Short Term Mood Changes
The most noticeable improvements occurred on the actual dosing days. Participants reported higher levels of creativity, energy, and social connectedness compared to the following days. Feelings of happiness appeared to remain elevated for up to two days after dosing, while irritability scores decreased.
These findings are particularly relevant because depression often reduces motivation, pleasure, and social engagement. Researchers suggested that temporary increases in emotional energy and connectedness could help patients participate more actively in rewarding activities and relationships.
Interestingly, participants did not report rapid tolerance developing over the eight weeks. The perceived strength of the drug’s effects remained relatively stable throughout the study. In psychopharmacology, this stability is notable because many psychiatric medications lose effectiveness over time as the brain adapts to repeated exposure.
Why The Study’s Design Still Leaves Important Questions
Although the results may appear encouraging, the researchers emphasized that the study was exploratory and contained significant limitations. The trial was open-label, meaning participants knew they were receiving LSD rather than a placebo.
This matters because expectations can strongly influence outcomes in psychiatric research. Individuals hoping for improvement may unconsciously report better mood states simply because they believe the treatment will help.
The study also involved only nineteen participants, most of whom were male and already taking standard antidepressant medications. This makes it difficult to determine how LSD microdosing alone contributed to the observed mood changes.
Despite these limitations, the trial demonstrated that participants could safely manage a structured at-home microdosing regimen with remote monitoring and dose adjustments. That practical finding may help shape future large-scale psychedelic research protocols.
What LSD Microdosing Research Could Mean For Psychiatry
The broader significance of this study lies in how it expands the conversation around individualized psychiatric treatment. Psychedelic compounds are increasingly being investigated not only for depression, but also for anxiety disorders, post-traumatic stress disorder, and addiction.
Researchers now need randomized, double blind clinical trials comparing LSD microdosing directly against placebo treatments. Those studies will be essential for determining whether the emotional improvements observed here reflect true pharmacological effects or powerful expectancy responses.
For now, the findings add another layer to the rapidly evolving field of psychedelic medicine. While microdosing remains experimental, studies like this continue to shape conversations about how future psychiatric treatments might become more personalized, flexible, and biologically targeted.
Citations
- Daldegan-Bueno D, Donegan CJ, Sumner R, et al. “LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial.” Progress in Neuropsychopharmacology & Biological Psychiatry (2026).
- https://doi.org/10.1016/j.pnpbp.2026.111522
- Petrova K. “LSD microdosing linked to acute mood improvements in adults with depression.” PsyPost (May 8, 2026). https://www.psypost.org/lsd-microdosing-linked-to-acute-mood-improvements-in-adults-with-depression/?utm_source=chatgpt.com
Explore more at https://www.interventionalpsychiatry.org/